Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus

Elena M. Wildasin, Debra J. Skaar, William R. Kirchain, Michelle Hulse

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Noninsulin-dependent diabetes mellitus has historically been treated with diet therapy alone or the addition of an oral hypoglycemic agent such as a sulfonylurea, or the two in combination with insulin. Although these medical interventions lower blood glucose concentrations, they may also potentiate hyperinsulinism through increased serum insulin concentrations. Insulin resistance and hyperinsulinism are associated with cardiovascular risk factors such as hypertriglyceridemia, decreased high-density lipoprotein cholesterol levels, hypertension, and hyperglycemia, among others. Therefore, a desirable therapeutic alternative would lower blood glucose, not result in hyperinsulinism, and have beneficial effects on lipid profiles. Metformin is a biguanide antihyperglycemic agent that provides these effects. When administered to carefully selected patients and monitored appropriately, metformin may prove to be valuable in the treatment of diabetes mellitus and in altering its cardiovascular sequelae.

Original languageEnglish (US)
Pages (from-to)62-73
Number of pages12
JournalPharmacotherapy
Volume17
Issue number1
StatePublished - Jan 1 1997

Fingerprint Dive into the research topics of 'Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus'. Together they form a unique fingerprint.

  • Cite this